Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis

Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis

Objective To systematically evaluate the efficacy and safety of combination regimens containing daratumumab in patients with multiple myeloma (MM). Methods A systematic search of publications listed on electronic databases (PubMed®, The Cochrane Library, Science Direct and Web of Science) between in...

Full description

Bibliographic Details
Main Authors:	Yin Wang, Yanqing Li, Ye Chai
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-08-01
Series:	Journal of International Medical Research
Online Access:	https://doi.org/10.1177/03000605211038135

Similar Items

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
by: Kristine A. Frerichs, et al.
Published: (2021-05-01)

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
by: Dima D, et al.
Published: (2020-08-01)

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA
by: V. V. Ryzhko, et al.
Published: (2017-11-01)

Daratumumab for the Treatment of Multiple Myeloma
by: Torben Plesner, et al.
Published: (2018-06-01)

Potential role of daratumumab in the treatment of multiple myeloma
by: Khagi Y, et al.
Published: (2014-06-01)

Daratumumab efficacy in extramedullary orbital myeloma
by: Alessandro Gozzetti, et al.
Published: (2020-12-01)

Clinical Efficacy of Daratumumab in Monotherapy of Relapsed/Refractory Multiple Myeloma
by: SS Bessmeltsev, et al.
Published: (2019-12-01)

Daratumumab treatment increases the risk of upper respiratory tract infections in multiple myeloma : A systematic review and meta-analysis
by: Mayerhofer, Raphaela
Published: (2020)

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
by: Alessandro Gozzetti, et al.
Published: (2020-12-01)

Daratumumab and its efficacy in refractory myeloma with anemia
by: Suresh Kumar Bondili, et al.
Published: (2020-01-01)

Daratumumab in untreated newly diagnosed multiple myeloma
by: Nadine Abdallah, et al.
Published: (2019-12-01)

Daratumumab – breakthrough drug in multiple myeloma therapy
by: Artur Jurczyszyn, et al.
Published: (2014-11-01)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
by: Torben Plesner
Published: (2021-03-01)

New developments in the treatment of multiple myeloma – clinical utility of daratumumab
by: McEllistrim C, et al.
Published: (2017-04-01)

Resolving crossmatch incompatibility due to daratumumab in multiple myeloma
by: S Anuragaa, et al.
Published: (2020-01-01)

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
by: Marina Zajec, et al.
Published: (2020-08-01)

Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? – Literature review
by: Luana Mota Ferreira, et al.
Published: (2021-04-01)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma.
by: Hareth Nahi, et al.
Published: (2019-01-01)

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
by: Larysa Sanchez, et al.
Published: (2016-06-01)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
by: Ilaria Saltarella, et al.
Published: (2020-01-01)

Experience of Daratumumab in Six Patients With Multiple Myeloma and Kidney Failure
by: Atakan Turgutkaya, et al.
Published: (2021-09-01)

Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
by: Tracy King, et al.
Published: (2018-01-01)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
by: Massimo Offidani, et al.
Published: (2021-02-01)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
by: Lakshmi Yarlagadda, et al.
Published: (2021-08-01)

Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study
by: E. Terpos, et al.
Published: (2020-10-01)

Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials
by: Shu-Kai Qiao, et al.
Published: (2015-01-01)

Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
by: Muhammad Husnain, et al.
Published: (2016-01-01)

Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
by: Husnain, Muhammad, et al.
Published: (2016)

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
by: Larysa Sanchez, et al.
Published: (2021-01-01)

Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population
by: Jiri Minarik, et al.
Published: (2019-09-01)

Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
by: Soma Agrawal, et al.
Published: (2020-01-01)

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma
by: Adrián Alegre, et al.
Published: (2020-06-01)

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
by: Francesca Cottini, et al.
Published: (2021-02-01)

Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma
by: Yaohua Cao, et al.
Published: (2021-03-01)

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
by: Kristine A. Frerichs, et al.
Published: (2019-12-01)

Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta‐analysis
by: Congcong Cao, et al.
Published: (2021-08-01)

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
by: Joseph Mikhael, et al.
Published: (2021-05-01)

Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
by: Jayeeta Ghose, et al.
Published: (2018-10-01)

Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
by: Gopalakrishnan S, et al.
Published: (2013-04-01)

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
by: Katja Weisel, et al.
Published: (2020-08-01)